AG
ALXN

Advisor Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Advisor Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1.5M Buy
13,857
+2,532
+22% +$271K 0.01% 964
2019
Q3 		$1.11M Buy
11,325
+626
+6% +$70.6K 0.01% 1082
2019
Q2 		$1.4M Buy
10,699
+1,619
+18% +$209K 0.01% 930
2019
Q1 		$1.23M Buy
9,080
+1,881
+26% +$234K 0.01% 970
2018
Q4 		$701K Sell
7,199
-118
-2% -$13.9K 0.01% 1176
2018
Q3 		$1.02M Buy
7,317
+1,901
+35% +$238K 0.01% 965
2018
Q2 		$672K Buy
5,416
+202
+4% +$23.6K 0.01% 1117
2018
Q1 		$581K Sell
5,214
-216
-4% -$25.8K 0.01% 1212
2017
Q4 		$649K Buy
5,430
+906
+20% +$110K 0.01% 1159
2017
Q3 		$635K Buy
4,524
+288
+7% +$39.1K 0.01% 1059
2017
Q2 		$515K Buy
4,236
+860
+25% +$100K 0.01% 1126
2017
Q1 		$409K Buy
3,376
+430
+15% +$55.4K 0.01% 1194
2016
Q4 		$361K Sell
2,946
-667
-18% -$81.6K 0.01% 1195
2016
Q3 		$442K Buy
3,613
+200
+6% +$25.7K 0.01% 1035
2016
Q2 		$396K Buy
+3,413
New +$484K 0.01% 1043

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisor Group's ALXN Position: Q4 2019 in Review

Advisor Group increased its Alexion Pharmaceuticals (ALXN) stake by 22% in Q4 2019, buying an estimated $271K and bringing the position to 13,857 shares worth $1.5M. The position accounts for 0.01% of the portfolio, ranked #964.

Advisor Group first reported a position in ALXN in Q2 2016 and has held it in 15 quarters since. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Advisor Group held 13,857 shares of Alexion Pharmaceuticals worth $1.5M as of Q4 2019.
  • Advisor Group bought 2,532 Alexion Pharmaceuticals shares in Q4 2019, an estimated $271K.
  • Alexion Pharmaceuticals made up 0.01% of Advisor Group's portfolio in Q4 2019, its #964 holding.
  • Advisor Group first reported a position in Alexion Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.